|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122780 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-17 15:04:52 |
|
注册时间: Date of Registration: |
2026-04-17 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
衰老过程中人胸腺和外周T细胞功能的研究 |
|
Public title: |
Studies on the Functional Changes of Human Thymic and Peripheral T Cells during Aging |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
衰老过程中人胸腺和外周T细胞功能的研究 |
|
Scientific title: |
Studies on the Functional Changes of Human Thymic and Peripheral T Cells during Aging |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
田钦 |
研究负责人: |
王小文 |
|
Applicant: |
Tian Qin |
Study leader: |
Wang Xiaowen |
|
申请注册联系人电话: Applicant telephone: |
+86 23 89011010 |
研究负责人电话: Study leader's telephone: |
+86 23 89011010 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
924750734@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
xiaowenwang@yeah.net |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市袁家岗友谊路1号 |
研究负责人通讯地址: |
重庆市袁家岗友谊路1号 |
|
Applicant address: |
No. 1 Youyi Road, Yuanjiagang, Chongqing, China |
Study leader's address: |
No. 1 Youyi Road, Yuanjiagang, Chongqing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学附属第一医院 |
||
|
Applicant's institution: |
The First Af?liated Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025年科研伦审(2025-686-01) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属第一医院医学研究伦理审查委员会 |
||
|
Name of the ethic committee: |
Medical Research Ethics Review Committee of the First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-21 00:00:00 |
||
|
伦理委员会联系人: |
严青 |
||
|
Contact Name of the ethic committee: |
Yan Qing |
||
|
伦理委员会联系地址: |
重庆市袁家岗友谊路1号 |
||
|
Contact Address of the ethic committee: |
No. 1 Youyi Road, Yuanjiagang, Chongqing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 89011876 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
444158752@qq.com |
|
研究实施负责(组长)单位: |
重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市袁家岗友谊路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1 Youyi Road, Yuanjiagang, Chongqing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2024重庆医科大学校园联合引才经费(胡洪波) |
||||||||||||||||||||||
|
Source(s) of funding: |
2024 Chongqing Medical University Campus Joint Talent Recruitment Fund |
||||||||||||||||||||||
|
Target disease: |
none |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
析因分组(即根据危险因素或暴露因素分组) |
||||||||||||||||||||||
|
Study design: |
Factorial |
||||||||||||||||||||||
|
研究目的: |
本研究拟利用二代测序技术和功能学实验,来研究人胸腺老化过程中胸腺及外周T细胞的变化与功能,以及这些变化与功能的生物学意义,为寻找逆转胸腺老化奠定基础。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study intends to use next-generation sequencing technology and functional experiments to investigate the changes and functions of the thymus and peripheral T cells during human thymic aging, as well as the biological significance of these changes and functions, laying a foundation for finding ways to reverse thymic aging. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.接受心脏矫形手术; 2.无其他已知疾病; 3.在手术过程中进行胸腺全切除、部分切除的患者,胸腺部分切除患者的切除比例根据术前、术后胸部CT影像学数据进行计算。 4.纳入年龄:青年(12-30岁)、中老年(30-60岁)、老年(60岁以上)。每个年龄组入组胸腺全切除和部分切除患者各3例(性别一致)。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Undergoing cardiac orthopedic surgery; 2. Having no other known diseases; 3. For patients undergoing total thymectomy or partial thymectomy during the operation, the resection ratio of patients with partial thymectomy is calculated based on preoperative and postoperative chest CT imaging data. 4. Included age groups: young people (12-30 years old), middle-aged and elderly people (30-60 years old), and elderly people (over 60 years old). In each age group, 3 patients with total thymectomy and 3 patients with partial thymectomy are included (with consistent gender). |
||||||||||||||||||||||
|
排除标准: |
吸烟者、有癌症病史、有慢性炎症性疾病(关节炎、克罗恩病、结肠炎、皮炎、纤维肌痛以及红斑狼疮)、HIV感染、乙型肝炎和丙型肝炎以及自身免疫疾病等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Smokers, those with a history of cancer, those with chronic inflammatory diseases (arthritis, Crohn's disease, colitis, dermatitis, fibromyalgia, and lupus), HIV infection, hepatitis B, hepatitis C, and autoimmune diseases, among others. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2026-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-10-21 00:00:00 至 To 2026-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
待研究结束后,相关结果及原始数据将通过发表学术论文的方式公开共享。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Upon completion of the study, the relevant results and raw data will be publicly shared through the publication of academic papers. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据存储于医院或研究团队加密服务器,数据加密后上传至阿里云或其他商业云 OSS(仅研究团队核心成员拥有解密密钥),定期进行漏洞扫描和数据备份。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data is stored on encrypted servers of hospitals or research teams. After encryption, the data is uploaded to Alibaba Cloud or other commercial cloud OSS (only core members of the research team have the decryption key). Vulnerability scanning and data backup are conducted regularly. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |